Domů › Rakovina vaječníků › Alabama › Birmingham
Klinické studie Rakovina vaječníků v Birmingham, AL
23 studií pro Rakovina vaječníků hledá účastníky v lokalitách v Birmingham a okolí (do cca 30 mil). Otevřete studii a zjistěte, kdo se může zapojit a jak kontaktovat tým studie.
Oficiální text studie (anglicky)
Hledáte účastníky pro studii? Zvýrazněte ji nahoře na této stránce – $99 na 30 dní →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Probíhá náborFáze 2
- University of Alabama at Birmingham Cancer Center, Birmingham
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Probíhá náborFáze 2
- UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital, Birmingham
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Probíhá náborFáze 2
- University of Alabama at Birmingham (UAB) Hospital /ID# 274793, Birmingham
DESTINY-PANTUMOUR04
Probíhá náborObservační studie
- Research Site, Birmingham
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Probíhá náborFáze 1/2
- University of Alabama_6th Ave, Birmingham
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Probíhá náborFáze 3
- University of Alabama at Birmingham, Birmingham
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Probíhá náborFáze 3
- University of Alabama - Birmingham ( Site 0058), Birmingham
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Probíhá náborObservační studie
- University of Alabama at Birmingham, Birmingham
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Probíhá náborFáze 2
- The University of Alabama at Birmingham, Birmingham
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Probíhá náborFáze 1/2
- The University of Alabama, Birmingham
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Probíhá náborFáze 1
- University of Alabama Birmingham, Birmingham
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Probíhá náborFáze 3
- University of Alabama at Birmingham ( Site 0006), Birmingham
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Probíhá náborFáze 1/2
- Children's Hospital of Alabama, Birmingham
Study of NTB-928 in R/R OC
Probíhá náborFáze 1
- The University of Alabama, Birmingham
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Probíhá nábor
- University of Alabama at Birmingham Cancer Center, Birmingham
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Probíhá náborFáze 3
- University of Alabama at Birmingham Cancer Center, Birmingham
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Probíhá náborFáze 1/2
- University of Alabama at Birmingham, Birmingham
The DETECT Study: Discovery and Evaluation of Testing for Endometrial and Ovarian Cancer in Tampons
Probíhá náborObservační studieVítáni zdraví dobrovolníci
- University of Alabama at Birmingham, Birmingham
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Probíhá náborFáze 2
- 004, Birmingham
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Probíhá náborFáze 2
- University of Alabama at Birmingham Womens & Infants Center, Birmingham
Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro
Probíhá náborFáze 2
- O'Neal Comprehensive Cancer Center at UAB, Birmingham
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Probíhá nábor
- University of Alabama at Birmingham, Birmingham
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Probíhá náborObservační studie
- Massive Bio SYNERGY-AI site, Birmingham
Studie Rakovina vaječníků v jiných městech
- Houston, TX89 studií
- New York City, NY69 studií
- Boston, MA61 studií
- Los Angeles, CA50 studií
- Nashville, TN49 studií
- Arlington, VA46 studií
- Philadelphia, PA44 studií
- Columbus, OH39 studií
- St. Louis, MO38 studií
- Chicago, IL36 studií
- San Antonio, TX31 studií
- Cleveland, OH30 studií
Další studie v Birmingham
- Rakovina (všechny typy)31 studií
- Rakovina prsu24 studií
- Obesity23 studií
- Nemalobuněčný plicní karcinom22 studií
- Akutní myeloidní leukemie21 studií
- Mnohočetný myelom18 studií
- CHOPN17 studií
- Kardiovaskulární onemocnění17 studií
- Diabetes mellitus 2. typu16 studií
- Rakovina endometria16 studií
- Nadváha16 studií
- Cystická fibróza16 studií
Zdroj: ClinicalTrials.gov, data načtena 6. 10. 2026. Každá studie má vlastní kritéria způsobilosti; o účasti rozhoduje tým studie.